The MyPathway basket trial further validated the potential of dual-antibody therapy, reporting an ORR of 38% in the HER2-amplified colorectal cancer cohort treated with trastuzumab plus pertuzumab, alongside median PFS and OS of 5.3 months and 10.9 months, respectively, with partial intracranial lesion responses observed in some cases (8). Here, ERBB2 is linked to colorectal cancer.